Clinical diagnostic laboratories continue to face growing pressure from rising test volumes, increasingly complex testing menus, significant workforce shortages, and expectations for faster turnaround times at sustainable cost. Total laboratory automation (TLA) has become a central strategy for improving efficiency in high-volume laboratories, where integrated systems from Abbott, Roche, Siemens Healthineers, and Beckman Coulter have demonstrated substantial reductions in turnaround time, error rates, and labor requirements. Evidence across multiple health systems shows that TLA improves performance and stabilizes laboratory operations even during workload peaks. Despite these gains, large segments of pre-analytical and post-analytical workflows remain manual, especially tasks related to specimen transportation, bench-level manipulation, instrument tending, and troubleshooting. Recent progress in collaborative robotics (cobots), autonomous mobile robots (AMRs), and hospital service robots demonstrates that these technologies can complement TLA by addressing not only the logistical and dexterous tasks that fixed automation lines cannot reach but also enabling robots that can work safely right alongside humans in a shared space. Cobots have shown sub-millimeter precision in colony picking and other fine-motor tasks, though typically at lower throughputs than dedicated track modules, and AMRs have demonstrated reliable transport of pathology carts and medical supplies through large clinical environments. Meanwhile, humanoid-capable mobile manipulators, like Moxi from Diligent Robotics, deployed in hospitals are already completing hundreds of thousands of supply deliveries, indicating real-world significance. Here, we integrate technical, regulatory, operational, and business perspectives on TLA, collaborative robotics, and mobile platforms. We discuss real-world efficiency gains, regulatory expectations under the CLIA and United States FDA, and the emerging case for hybrid automation ecosystems that combine TLA islands, cobotic workcells, AMRs, and AI-enabled orchestration. We argue that the next decade of laboratory automation will move beyond monolithic tracks with robots toward flexible, modular robotic systems designed to operate safely together with humans and to augment the increasingly strained laboratory workforce. This not only allows clinical staff to dedicate more time to patient care but also ensures greater reliability and scalability for essential services throughout demanding hospital environments.

Background and Objectives: Diagnostics for hematologic diseases rely on integrated assessment of clinical manifestation, morphology, flow cytometry, and molecular testing. Current classification systems, including the WHO HAEM5 and the International Consensus Classification, highlight the central role of genomics in defining disease entities and risk. Simultaneously, laboratories face growing case complexity and staffing challenges. Automation, collaborative robots (cobots), digital morphology platforms, and artificial intelligence (AI) have begun to address these issues. Here we examine the application of these technologies in hematopathology and molecular diagnostics and consider their translational potential to improve diagnostic accuracy and, ultimately, patient care. Methods: A review of peer-reviewed literature and technical reports published through December 2025 was performed, focusing on digital morphology platforms, AI for peripheral blood and marrow interpretation, AI-enabled flow cytometry, automated and robotic deployments in clinical laboratories, and machine learning applications in molecular hematopathology. Results: Digital morphology analyzers show strong concordance with manual microscopy and now serve as efficient platforms for AI-assisted differentials, cell classification, and fibrosis quantification. Deep learning applied to multiparameter flow cytometry achieves performance comparable to expert review in distinguishing mature B-cell neoplasms and acute leukemias. Automated solutions, cobot systems and robotic-arm-based slide-scanning clusters have demonstrated substantial gains in throughput and pre-analytic consistency. AI models in molecular hematopathology increasingly assist with variant interpretation, genetic risk stratification, and linking morphologic and genomic findings. Conclusions: AI is beginning to change how hematopathology and molecular diagnostics are practiced. Successful translation will depend on disease-specific validation, the development of multi-modal models aligned with ICC and WHO frameworks, and laboratory governance that maintains expert oversight.